Robert W. Baird analyst Michael Ulz reiterated a Buy rating on Blueprint Medicines (NASDAQ:BPMC) on Thursday, setting a price target of $120, which is approximately 24.04% above the present share price of $96.74.
Ulz expects Blueprint Medicines to post earnings per share (EPS) of $11.49 for the first quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Blueprint Medicines, with an average price target of $118.09.
The analysts price targets range from a high of $152 to a low of $81.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $745.12 million and a net profit of $633.37 million. The company's market cap is $5.39 billion.
According to TipRanks.com, Robert W. Baird analyst Michael Ulz is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.6% and a 52.63% success rate.
Blueprint Medicines Corp . is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.